BioCentury
ARTICLE | Clinical News

Rival RET inhibitor data highlighted at thyroid meeting

October 8, 2018 8:32 PM UTC

Loxo Oncology Inc. (NASDAQ:LOXO) and Blueprint Medicines Corp. (NASDAQ:BPMC) each reported updated data on Saturday at the American Thyroid Association meeting in Washington from clinical trials evaluating their respective ret proto-oncogene (RET) inhibitors to treat RET-altered cancers.

Loxo said the Phase I/II LIBRETTO-001 trial showed that LOXO-292 led to a confirmed overall response rate (ORR) of 56%, including two complete responses (CRs) and 13 partial responses (PRs), in 29 evaluable RET-mutant medullary thyroid cancer (MTC) patients. In nine evaluable RET fusion-positive thyroid cancer patients, LOXO-292 led to a confirmed ORR of 78%, including seven PRs. The data include 3.5 months of additional follow-up since data were first reported from the trial at the American Society of Clinical Oncology meeting in June...